CRMD News and Press, CorMedix Inc. From 05/14/23

2023-05-14 17:35:00 ET CorMedix ( NASDAQ: CRMD ) is scheduled to announce Q1 earnings results on Monday, May 15th, after market close. The consensus EPS Estimate is -$0.20 Over the last 3 months, EPS estimates have seen 1 upward revision and 0 downward. For f...

BERKELEY HEIGHTS, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that it will report i...

BERKELEY HEIGHTS, N.J., May 03, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced that management will ...

2023-05-01 12:20:21 ET CorMedix ( NASDAQ: CRMD ) said it had received United States Patent and Trademark Office (USPTO) allowance for its patent claims on a catheter lock solution that can prevent infection and reduced blood flow in central venous catheters. CorMedix receives ...

BERKELEY HEIGHTS, N.J., May 01, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that the United States Pa...

BERKELEY HEIGHTS, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced that following its Type...

BERKELEY HEIGHTS, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases, today announced the appointment of Robe...

2023-03-30 12:51:02 ET CorMedix Inc. (CRMD) Q4 2022 Earnings Conference Call March 30, 2023 8:30 AM ET Company Participants Dan Ferry – Managing Director-LifeSci Advisors Joe Todisco – Chief Executive Officer Matt David – Executive Vice Presi...

2023-03-30 07:32:20 ET CorMedix press release ( NASDAQ: CRMD ): Q4 GAAP EPS of -$0.20 misses by $0.01 . Revenue of $0.03M (-50.0% Y/Y) beats by $0.03M . Cash and short-term investments, excluding restricted cash, at December 31, 2022 amounted to $58.8M. F...

BERKELEY HEIGHTS, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced financial results for t...